Shares of KemPharm Inc. (NASDAQ:KMPH) shot up 12.8% during trading on Wednesday . The stock traded as high as $5.50 and last traded at $5.37, with a volume of 229,909 shares changing hands. The stock had previously closed at $4.76.

Several equities analysts have recently issued reports on KMPH shares. Oppenheimer Holdings Inc. restated a “buy” rating on shares of KemPharm in a report on Saturday, May 14th. Canaccord Genuity reiterated a “buy” rating on shares of KemPharm in a report on Saturday, May 14th. Royal Bank Of Canada reiterated a “buy” rating on shares of KemPharm in a report on Sunday, May 8th. Finally, Zacks Investment Research downgraded shares of KemPharm from a “hold” rating to a “sell” rating in a report on Wednesday, May 4th.

The company has a 50 day moving average of $4.14 and a 200-day moving average of $10.25. The company’s market cap is $77.48 million.

KemPharm (NASDAQ:KMPH) last announced its quarterly earnings data on Wednesday, August 10th. The specialty pharmaceutical company reported ($0.58) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.94) by $0.36. Equities research analysts forecast that KemPharm Inc. will post ($2.44) earnings per share for the current year.

KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.